| Cat.No. | Name | Information |
|---|---|---|
| M2562 | ZCL278 | ZCL278 is a selective Cdc42 GTPase inhibitor with Kd of 11.4 μM. |
| M6282 | NSC 23766 | NSC 23766 is an inhibitor of Rac GTPase targeting Rac activation by guanine nucleotide exchange factors (GEFs) with IC50 of ~50 μM in a cell-free assay; does not inhibit the closely related targets, Cdc42 or RhoA. |
| M9356 | AMG-510 (Sotorasib) | AMG-510 (Sotorasib) is a potent KRAS G12C covalent inhibitor. |
| M9428 | MRTX849 (Adagrasib) | MRTX849 (Adagrasib) is a potent, highly selective, oral available KRAS G12C inhibitor. |
| M8999 | CCG-1423 | CCG-1423 is a novel specific inhibitor of RhoA transcriptional signaling. |
| M56320 | MLS-573151 | MLS-573151 (MLS000573151) is a selective GTPase Cdc42 inhibitor with an EC50 of 2 μM. |
| M56319 | K-Ras G12C-IN-3 | K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C. |
| M55031 | BBO-8520 | BBO-8520 is a first-in-class orally active covalent KRAS G12C inhibitor. BBO-8520 inhibits KRASG12C (ON) by locking the GTP-binding protein in state 1, a conformation incapable of binding effectors, thereby inhibiting the downstream signaling of KRASG12C (ON) that promotes cell proliferation. BBO-8520 also rapidly and completely blocks the RAS-RAF1 interaction, returning KRASG12C to its inactive (OFF) state. |
| M52906 | KRpep-2d | KRpep-2d is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. |
| M52905 | Rac1 Inhibitor W56 | Rac1 Inhibitor W56 is a peptide containing residues 45-60 of Rac1. |
| M52904 | SAH-SOS1A | SAH-SOS1A is a peptide-based SOS1/KRAS protein interaction inhibitor. |
| M49938 | Glecirasib | Glecirasib is a potent, irreversible, orally active KRAS G12C inhibitor for studies related to KRAS G12C-mediated cancers. |
| M49728 | K20 | K20 is a potent and selective KRas G12C inhibitor with an IC50 of 1.16 µM. |
| M49478 | RMC-8839 | RMC-8839 is an orally available, mutant-selective, direct inhibitor of KRAS G13C. |
| M49477 | YL-17231 | YL-17231 is a pan-KRAS mutant oral small molecule inhibitor in combination with the KRAS switch II pocket for studies related to KRAS mutant solid tumors. |
| M49368 | RM-032 | RM-032 is an orally active KRAS inhibitor that covalently binds to KRAS G12C and procyclin A to inhibit RAS pathway signaling and cell proliferation in KRAS G12C tumor cells. |
| M49367 | SML-8-73-1 | SML-8-73-1 is a GDP analog and also a KRAS inhibitor that irreversibly covalently binds to the GTPase active site of KRAS, and its binding rate to KRAS G12C was more than 95% in a 1 mmol/L GDP/GTP environment, and the IC 50 value for the inhibition of the proliferation of lung cancer cells H358 was 26.6 μmol/L . |
| M45215 | ABSK071 | ABSK071 is a novel KRAS G12C inhibitor with antitumor activity. |
| M45162 | BI 1823911 | BI 1823911 is a novel, highly selective, covalently irreversible oral small molecule inhibitor of KRASG12C. |
| M45161 | ARS-3248 | ARS-3248 is a novel KRAS G12C inhibitor. |
| M45160 | LY3499446 | LY3499446 is a KRAS G12C covalent inhibitor for studies related to non-small cell lung cancer (NSCLC). |
| M43844 | MK-1084 | MK-1084 is a KRAS G12C inhibitor that can be used in studies related to solid tumors. |
| M41938 | CFL-120 | CFL-120 is a potent KRasG12C inhibitor. |
| M41937 | CFL-137 | CFL-137 is a potent KRasG12C inhibitor. |
| M41936 | Oligomycin D | Oligomycin D (Rutamycin A) is an antibiotic. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
